Towa Pharmaceutical Statistics

Total Valuation

Towa Pharmaceutical has a market cap or net worth of JPY 158.51 billion. The enterprise value is 337.84 billion.

Market Cap	158.51B
Enterprise Value	337.84B

Important Dates

The next estimated earnings date is Thursday, February 13, 2025.

Earnings Date	Feb 13, 2025
Ex-Dividend Date	Mar 28, 2025

Share Statistics

Towa Pharmaceutical has 49.23 million shares outstanding. The number of shares has decreased by -0.00% in one year.

Current Share Class	n/a
Shares Outstanding	49.23M
Shares Change (YoY)	-0.00%
Shares Change (QoQ)	+0.01%
Owned by Insiders (%)	2.98%
Owned by Institutions (%)	18.27%
Float	24.50M

Valuation Ratios

The trailing PE ratio is 10.05 and the forward PE ratio is 10.09.

PE Ratio	10.05
Forward PE	10.09
PS Ratio	0.65
PB Ratio	1.00
P/TBV Ratio	1.42
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 8.45, with an EV/FCF ratio of -33.84.

EV / Earnings	21.42
EV / Sales	1.38
EV / EBITDA	8.45
EV / EBIT	15.97
EV / FCF	-33.84

Financial Position

The company has a current ratio of 3.04, with a Debt / Equity ratio of 1.39.

Current Ratio	3.04
Quick Ratio	1.39
Debt / Equity	1.39
Debt / EBITDA	5.52
Debt / FCF	-22.10
Interest Coverage	16.14

Financial Efficiency

Return on equity (ROE) is 10.31% and return on invested capital (ROIC) is 3.72%.

Return on Equity (ROE)	10.31%
Return on Assets (ROA)	3.16%
Return on Capital (ROIC)	3.72%
Revenue Per Employee	53.17M
Profits Per Employee	3.44M
Employee Count	4,588
Asset Turnover	0.58
Inventory Turnover	1.52

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +34.46% in the last 52 weeks. The beta is -0.09, so Towa Pharmaceutical's price volatility has been lower than the market average.

Beta (5Y)	-0.09
52-Week Price Change	+34.46%
50-Day Moving Average	2,986.92
200-Day Moving Average	2,924.50
Relative Strength Index (RSI)	64.02
Average Volume (20 Days)	129,200

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Towa Pharmaceutical had revenue of JPY 243.94 billion and earned 15.78 billion in profits. Earnings per share was 320.49.

Revenue	243.94B
Gross Profit	88.06B
Operating Income	21.16B
Pretax Income	24.37B
Net Income	15.78B
EBITDA	39.99B
EBIT	21.16B
Earnings Per Share (EPS)	320.49

Full Income Statement

Balance Sheet

The company has 41.27 billion in cash and 220.60 billion in debt, giving a net cash position of -179.33 billion or -3,642.87 per share.

Cash & Cash Equivalents	41.27B
Total Debt	220.60B
Net Cash	-179.33B
Net Cash Per Share	-3,642.87
Equity (Book Value)	159.11B
Book Value Per Share	3,232.16
Working Capital	152.54B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 21.39 billion and capital expenditures -31.37 billion, giving a free cash flow of -9.98 billion.

Operating Cash Flow	21.39B
Capital Expenditures	-31.37B
Free Cash Flow	-9.98B
FCF Per Share	-202.77

Full Cash Flow Statement

Margins

Gross margin is 36.10%, with operating and profit margins of 8.67% and 6.47%.

Gross Margin	36.10%
Operating Margin	8.67%
Pretax Margin	9.99%
Profit Margin	6.47%
EBITDA Margin	16.39%
EBIT Margin	8.67%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 60.00, which amounts to a dividend yield of 1.83%.

Dividend Per Share	60.00
Dividend Yield	1.83%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	18.38%
Buyback Yield	0.00%
Shareholder Yield	1.83%
Earnings Yield	9.95%
FCF Yield	-6.30%

Dividend Details

Stock Splits

The last stock split was on March 27, 2019. It was a forward split with a ratio of 3.

Last Split Date	Mar 27, 2019
Split Type	Forward
Split Ratio	3

Scores

Towa Pharmaceutical has an Altman Z-Score of 1.85. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.85
Piotroski F-Score	n/a